FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2015758051> ?p ?o ?g. }

• W2015758051 endingPage "2020" @default.
• W2015758051 startingPage "2007" @default.
• W2015758051 abstract "Sublines of K562 human leukemia cells were selected for resistance (30- to 80-fold) to etoposide by continuous exposure to 0.5 microM VP-16. Two etoposide-resistant cell lines, K/VP.5 and K/VP.5-1, showed a 5-fold reduction in levels of topoisomerase II alpha protein compared with K562 cells. Northern analysis indicated a 2.5-fold reduction in topoisomerase II alpha mRNA in etoposide-resistant cell lines, due in part to a 1.7-fold decrease in topoisomerase II mRNA stability with no change in transcription rate. Immunoblotting assays of electrophoresed cell lysates from VP-16-treated cells revealed less drug-induced covalent topoisomerase II/DNA adducts in resistant than in sensitive cells, suggesting a functional alteration in resistant cell topoisomerase II. Recent reports of specific topoisomerase II DNA binding sites near the promoter sites of growth response genes and alterations of gene expression in cells treated with topoisomerase II inhibitory drugs led to experiments to determine if the apparent functional alterations of topoisomerase II were accompanied by changes in the regulation of these genes. Therefore, the expression of several growth response genes was compared by northern analysis in parental K562 and both VP-16-resistant cell lines. Basal levels of c-myc were comparable for all three cell lines, but levels of c-jun and c-fos were elevated 2- to 4-fold in VP-16-resistant cell lines. Increased levels of c-fos and c-jun were not a result of altered rates of transcription, as determined by nuclear run-off assays. Exposure of both sensitive and resistant cells to 200 microM VP-16 for 5 hr resulted in no further changes in topoisomerase II mRNA levels but caused an additional 2- to 3-fold elevation in the level of c-jun mRNA, indicating that altered basal levels of this gene were not due to deregulation of this gene. Acquired VP-16 resistance in K/VP.5 and K/VP.5-1 cells was accompanied by reduced levels and altered activities of DNA topoisomerase II as well as changes affecting the expression of genes important for growth and differentiation." @default.
• W2015758051 created "2016-06-24" @default.
• W2015758051 creator A5005459076 @default.
• W2015758051 creator A5080340455 @default.
• W2015758051 date "1993-12-01" @default.
• W2015758051 modified "2023-10-16" @default.
• W2015758051 title "Altered gene expression in human leukemia K562 cells selected for resistance to etoposide" @default.
• W2015758051 cites W1512813342 @default.
• W2015758051 cites W1558579604 @default.
• W2015758051 cites W1579393067 @default.
• W2015758051 cites W1586201322 @default.
• W2015758051 cites W1592664042 @default.
• W2015758051 cites W1595993539 @default.
• W2015758051 cites W1760280961 @default.
• W2015758051 cites W1833690096 @default.
• W2015758051 cites W1959713421 @default.
• W2015758051 cites W1971099028 @default.
• W2015758051 cites W1971105285 @default.
• W2015758051 cites W1974325040 @default.
• W2015758051 cites W1976750415 @default.
• W2015758051 cites W1979094638 @default.
• W2015758051 cites W1979230039 @default.
• W2015758051 cites W1982470282 @default.
• W2015758051 cites W1982735947 @default.
• W2015758051 cites W1988085635 @default.
• W2015758051 cites W1991220558 @default.
• W2015758051 cites W1995978120 @default.
• W2015758051 cites W1999964184 @default.
• W2015758051 cites W2009886925 @default.
• W2015758051 cites W2012754297 @default.
• W2015758051 cites W2029375782 @default.
• W2015758051 cites W2029399500 @default.
• W2015758051 cites W2033995562 @default.
• W2015758051 cites W2042367294 @default.
• W2015758051 cites W2045412127 @default.
• W2015758051 cites W2045798063 @default.
• W2015758051 cites W2047632936 @default.
• W2015758051 cites W2048154652 @default.
• W2015758051 cites W2058744360 @default.
• W2015758051 cites W2069251269 @default.
• W2015758051 cites W2081643570 @default.
• W2015758051 cites W2093668404 @default.
• W2015758051 cites W2094872845 @default.
• W2015758051 cites W2097878215 @default.
• W2015758051 cites W2102345056 @default.
• W2015758051 cites W2105933407 @default.
• W2015758051 cites W2111841684 @default.
• W2015758051 cites W2124551132 @default.
• W2015758051 cites W2127067451 @default.
• W2015758051 cites W2134793597 @default.
• W2015758051 cites W2164515753 @default.
• W2015758051 cites W2166347628 @default.
• W2015758051 cites W253728726 @default.
• W2015758051 cites W4233567369 @default.
• W2015758051 cites W4241915111 @default.
• W2015758051 cites W4246606322 @default.
• W2015758051 cites W4294216491 @default.
• W2015758051 doi "https://doi.org/10.1016/0006-2952(93)90643-b" @default.
• W2015758051 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8267650" @default.
• W2015758051 hasPublicationYear "1993" @default.
• W2015758051 type Work @default.
• W2015758051 sameAs 2015758051 @default.
• W2015758051 citedByCount "46" @default.
• W2015758051 countsByYear W20157580512012 @default.
• W2015758051 countsByYear W20157580512014 @default.
• W2015758051 countsByYear W20157580512015 @default.
• W2015758051 countsByYear W20157580512016 @default.
• W2015758051 countsByYear W20157580512018 @default.
• W2015758051 countsByYear W20157580512019 @default.
• W2015758051 countsByYear W20157580512020 @default.
• W2015758051 countsByYear W20157580512021 @default.
• W2015758051 countsByYear W20157580512022 @default.
• W2015758051 countsByYear W20157580512023 @default.
• W2015758051 crossrefType "journal-article" @default.
• W2015758051 hasAuthorship W2015758051A5005459076 @default.
• W2015758051 hasAuthorship W2015758051A5080340455 @default.
• W2015758051 hasConcept C104317684 @default.
• W2015758051 hasConcept C138885662 @default.
• W2015758051 hasConcept C147897179 @default.
• W2015758051 hasConcept C150194340 @default.
• W2015758051 hasConcept C153911025 @default.
• W2015758051 hasConcept C171122931 @default.
• W2015758051 hasConcept C179926584 @default.
• W2015758051 hasConcept C2776694085 @default.
• W2015758051 hasConcept C2778119113 @default.
• W2015758051 hasConcept C41895202 @default.
• W2015758051 hasConcept C54355233 @default.
• W2015758051 hasConcept C552990157 @default.
• W2015758051 hasConcept C55493867 @default.
• W2015758051 hasConcept C62112901 @default.
• W2015758051 hasConcept C81885089 @default.
• W2015758051 hasConcept C86803240 @default.
• W2015758051 hasConceptScore W2015758051C104317684 @default.
• W2015758051 hasConceptScore W2015758051C138885662 @default.
• W2015758051 hasConceptScore W2015758051C147897179 @default.
• W2015758051 hasConceptScore W2015758051C150194340 @default.
• W2015758051 hasConceptScore W2015758051C153911025 @default.
• W2015758051 hasConceptScore W2015758051C171122931 @default.

• next